{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:21:39Z","timestamp":1751430099957,"version":"3.41.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.7759\/cureus.87128","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:47:41Z","timestamp":1751399261000},"source":"Crossref","is-referenced-by-count":0,"title":["Sodium 2-Mercaptoethanesulfonate (MESNA), Ifosfamide, Mitoxantrone, and Etoposide (MINE) in Transplant-Ineligible Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Is the Old Regimen Still Gold?"],"prefix":"10.7759","author":[{"given":"Leonardo","family":"Maia Mo\u00e7o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Hortas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gon\u00e7alo","family":"de C\u00e2mara Negalha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Br\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio","family":"Mariz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li S","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018, 50:74-87. 10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump M","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al.. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017, 130:1800-8. 10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil LJ","year":"2023","unstructured":"Nastoupil LJ, Bartlett NL. Navigating the evolving treatment landscape of diffuse large B-cell lymphoma. J Clin Oncol. 2023, 41:903-13. 10.1200\/JCO.22.01848","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1734","article-title":"Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP","volume":"13","author":"Rodriguez MA","year":"1995","unstructured":"Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995, 13:1734-41. 10.1200\/JCO.1995.13.7.1734","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702793","article-title":"Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival","volume":"27","author":"van Besien K","year":"2001","unstructured":"van Besien K, Rodriguez A, Tomany S, et al.. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001, 27:397-404. 10.1038\/sj.bmt.1702793","journal-title":"Bone Marrow Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.4954.4954","article-title":"Rituximab + IEV\/MINE second line approach in relapsed\/refractory non Hodgkin lymphoma (NHL): efficacy and safety","volume":"112","author":"Bongarzoni V","year":"2008","unstructured":"Bongarzoni V, Anaclerico B, Borza PA, et al.. Rituximab + IEV\/MINE second line approach in relapsed\/refractory non Hodgkin lymphoma (NHL): efficacy and safety. Blood. 2008, 112:4954. 10.1182\/blood.V112.11.4954.4954","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1901090","article-title":"Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation","volume":"62","author":"Cazelles C","year":"2021","unstructured":"Cazelles C, Belhadj K, Vellemans H, et al.. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leuk Lymphoma. 2021, 62:2161-8. 10.1080\/10428194.2021.1901090","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208111","article-title":"Outcomes of relapsed or refractory diffuse large B-cell lymphoma treated with R-GemOx: a multi-center retrospective cohort study","volume":"144","author":"Yamshon S","year":"2024","unstructured":"Yamshon S, Koff JL, Larson MC, et al.. Outcomes of relapsed or refractory diffuse large B-cell lymphoma treated with R-GemOx: a multi-center retrospective cohort study. Blood. 2024, 144:3093. 10.1182\/blood-2024-208111","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.010","article-title":"Real-world survival, healthcare resource utilization, and costs among U.S. elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with R-GEMOX in the relapsed\/refractory setting","volume":"24","author":"Garg M","year":"2024","unstructured":"Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland KE, Doshi JA, Huntington SF. Real-world survival, healthcare resource utilization, and costs among U.S. elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with R-GEMOX in the relapsed\/refractory setting. Clin Lymphoma Myeloma Leuk. 2024, 24:181-90. 10.1016\/j.clml.2024.01.010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148039","article-title":"Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Locke FL","year":"2021","unstructured":"Locke FL, Miklos DB, Jacobson C, et al.. Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed\/refractory large B-cell lymphoma. Blood. 2021, 138:2. 10.1182\/blood-2021-148039","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson JS","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, et al.. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023, 141:1675-84. 10.1182\/blood.2022018730","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot R","year":"2023","unstructured":"Houot R, Bachy E, Cartron G, et al.. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023, 29:2593-601. 10.1038\/s41591-023-02572-5","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster SJ","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, et al.. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021, 22:1403-15. 10.1016\/S1470-2045(21)00375-2","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-155068","article-title":"Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III BELINDA study","volume":"138","author":"Bishop MR","year":"2021","unstructured":"Bishop MR, Dickinson M, Purtill D, et al.. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III BELINDA study. Blood. 2021, 138:6. 10.1182\/blood-2021-155068","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson MJ","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, et al.. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022, 387:2220-31. 10.1056\/NEJMoa2206913","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett NL","year":"2023","unstructured":"Bartlett NL, Assouline S, Giri P, et al.. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023, 7:4926-35. 10.1182\/bloodadvances.2022009260","journal-title":"Blood Adv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont C","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H, et al.. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024, 38:2653-62. 10.1038\/s41375-024-02410-8","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot A","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, et al.. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016, 127:1410-16. 10.1182\/blood-2015-06-651380","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson JS","year":"2024","unstructured":"Abramson JS, Ku M, Hertzberg M, et al.. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024, 404:1940-54. 10.1016\/S0140-6736(24)01774-4","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial","volume":"145","author":"Brody JD","year":"2025","unstructured":"Brody JD, J\u00f8rgensen J, Belada D, et al.. Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 2025, 145:1621-31. 10.1182\/blood.2024026830","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02094-5","article-title":"Tafasitamab plus lenalidomide versus 3 rituximab-based treatments for non-transplant eligible relapsed\/refractory diffuse large B-cell lymphoma: a matching-adjusted indirect comparison","volume":"39","author":"Cordoba R","year":"2022","unstructured":"Cordoba R, Prawitz T, Westley T, Sharma A, Ambarkhane S, Kapetanakis V, Sabatelli L. Tafasitamab plus lenalidomide versus 3 rituximab-based treatments for non-transplant eligible relapsed\/refractory diffuse large B-cell lymphoma: a matching-adjusted indirect comparison. Adv Ther. 2022, 39:2668-87. 10.1007\/s12325-022-02094-5","journal-title":"Adv Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles G","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, et al.. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020, 21:978-88. 10.1016\/S1470-2045(20)30225-4","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-185992","article-title":"Tafasitamab and lenalidomide in relapsed\/refractory B-cell lymphoma: a multicenter retrospective real-world-study of patients from Germany and Austria","volume":"142","author":"Ruckdeschel A","year":"2023","unstructured":"Ruckdeschel A, Sabrina K, Topp MS, et al.. Tafasitamab and lenalidomide in relapsed\/refractory B-cell lymphoma: a multicenter retrospective real-world-study of patients from Germany and Austria. Blood. 2023, 142:1771.","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021274","article-title":"Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study","volume":"142","author":"Qualls DA","year":"2023","unstructured":"Qualls DA, Lambert N, Caimi PF, et al.. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023, 142:2327-31. 10.1182\/blood.2023021274","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173143","article-title":"Tafasitamab for the treatment of relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) in the US real-world setting","volume":"142","author":"Saverno K","year":"2023","unstructured":"Saverno K, Savill KMZ, Feinberg B, et al.. Tafasitamab for the treatment of relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) in the US real-world setting. Blood. 2023, 142:265. 10.1182\/blood-2023-173143","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157679","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): final results of a phase Ib\/II randomized study and single-arm extension (Ext) study","volume":"140","author":"Sehn LH","year":"2022","unstructured":"Sehn LH, Hertzberg M, Opat S, et al.. Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): final results of a phase Ib\/II randomized study and single-arm extension (Ext) study. Blood. 2022, 140:9464-7. 10.1182\/blood-2022-157679","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283459","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi PF","year":"2024","unstructured":"Caimi PF, Ai WZ, Alderuccio JP, et al.. Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024, 109:1184-93. 10.3324\/haematol.2023.283459","journal-title":"Haematologica"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian SH","year":"2015","unstructured":"Armenian SH, Hudson MM, Mulder RL, et al.. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015, 16:123-36. 10.1016\/S1470-2045(14)70409-7","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/366758-sodium-2-mercaptoethanesulfonate-mesna-ifosfamide-mitoxantrone-and-etoposide-mine-in-transplant-ineligible-relapsedrefractory-diffuse-large-b-cell-lymphoma-is-the-old-regimen-still-gold","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:47:43Z","timestamp":1751399263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/366758-sodium-2-mercaptoethanesulfonate-mesna-ifosfamide-mitoxantrone-and-etoposide-mine-in-transplant-ineligible-relapsedrefractory-diffuse-large-b-cell-lymphoma-is-the-old-regimen-still-gold"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.87128","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}